Prognostic Role of Androgen Receptor Expression in Surgically Resected Early Breast Cancer Patients
Endocrine therapy is a standard treatment for hormone receptor-positive breast cancer, which accounts for 60%-75% of all breast cancer. Hormone receptor positivity is a prognostic and predictive biomarker in breast cancer. Approximately 50%-80% of breast cancer is also positive for androgen receptor...
Saved in:
| Published in | Journal of breast cancer Vol. 23; no. 2; pp. 182 - 193 |
|---|---|
| Main Authors | , , , , , , , , , , , , , |
| Format | Journal Article |
| Language | English |
| Published |
Korea (South)
Korean Breast Cancer Society
01.04.2020
한국유방암학회 |
| Subjects | |
| Online Access | Get full text |
| ISSN | 1738-6756 2092-9900 2092-9900 |
| DOI | 10.4048/jbc.2020.23.e28 |
Cover
| Abstract | Endocrine therapy is a standard treatment for hormone receptor-positive breast cancer, which accounts for 60%-75% of all breast cancer. Hormone receptor positivity is a prognostic and predictive biomarker in breast cancer. Approximately 50%-80% of breast cancer is also positive for androgen receptor (AR), but the prognostic and predictive value of AR expression in breast cancer is controversial. Here, we investigated AR expression and its prognostic value in patients with surgically resected breast cancer in Korea.
We retrospectively reviewed the medical records of patients who had surgically resected breast cancer to collect AR expression data and other clinicopathological data. The optimal cut-off for AR positivity was determined using a receiver operating characteristic curve analysis.
We reviewed 957 patients with surgically resected breast cancer from June 2012 to April 2013. The median follow-up was 62 months, and relapse events occurred in 101 (10.6%) patients. Unlike the cut-off value of 1% or 10% in previous reports, 35% was determined to be best for predicting relapse-free survival (RFS) in this study. At the cut-off value of 35%, 654 (68.4%) patients were AR-positive. AR expression was more prevalent in luminal A (87.6%) and luminal B (73.1%) types than in human epidermal growth factor receptor 2-positive (56.2%) or triple-negative (20.6%) types. AR expression of ≥ 35% was significantly related to longer RFS in a multivariate analysis (hazard ratio, 0.430; 95% confidence interval, 0.260-0.709;
= 0.001).
We propose a cut-off value of 35% to best predict RFS in patients with surgically resected breast cancer. AR expression was positive in 68.4% of patients, and AR positivity was found to be an independent prognostic factor for longer RFS. |
|---|---|
| AbstractList | Endocrine therapy is a standard treatment for hormone receptor-positive breast cancer, which accounts for 60%-75% of all breast cancer. Hormone receptor positivity is a prognostic and predictive biomarker in breast cancer. Approximately 50%-80% of breast cancer is also positive for androgen receptor (AR), but the prognostic and predictive value of AR expression in breast cancer is controversial. Here, we investigated AR expression and its prognostic value in patients with surgically resected breast cancer in Korea.PURPOSEEndocrine therapy is a standard treatment for hormone receptor-positive breast cancer, which accounts for 60%-75% of all breast cancer. Hormone receptor positivity is a prognostic and predictive biomarker in breast cancer. Approximately 50%-80% of breast cancer is also positive for androgen receptor (AR), but the prognostic and predictive value of AR expression in breast cancer is controversial. Here, we investigated AR expression and its prognostic value in patients with surgically resected breast cancer in Korea.We retrospectively reviewed the medical records of patients who had surgically resected breast cancer to collect AR expression data and other clinicopathological data. The optimal cut-off for AR positivity was determined using a receiver operating characteristic curve analysis.METHODSWe retrospectively reviewed the medical records of patients who had surgically resected breast cancer to collect AR expression data and other clinicopathological data. The optimal cut-off for AR positivity was determined using a receiver operating characteristic curve analysis.We reviewed 957 patients with surgically resected breast cancer from June 2012 to April 2013. The median follow-up was 62 months, and relapse events occurred in 101 (10.6%) patients. Unlike the cut-off value of 1% or 10% in previous reports, 35% was determined to be best for predicting relapse-free survival (RFS) in this study. At the cut-off value of 35%, 654 (68.4%) patients were AR-positive. AR expression was more prevalent in luminal A (87.6%) and luminal B (73.1%) types than in human epidermal growth factor receptor 2-positive (56.2%) or triple-negative (20.6%) types. AR expression of ≥ 35% was significantly related to longer RFS in a multivariate analysis (hazard ratio, 0.430; 95% confidence interval, 0.260-0.709; p = 0.001).RESULTSWe reviewed 957 patients with surgically resected breast cancer from June 2012 to April 2013. The median follow-up was 62 months, and relapse events occurred in 101 (10.6%) patients. Unlike the cut-off value of 1% or 10% in previous reports, 35% was determined to be best for predicting relapse-free survival (RFS) in this study. At the cut-off value of 35%, 654 (68.4%) patients were AR-positive. AR expression was more prevalent in luminal A (87.6%) and luminal B (73.1%) types than in human epidermal growth factor receptor 2-positive (56.2%) or triple-negative (20.6%) types. AR expression of ≥ 35% was significantly related to longer RFS in a multivariate analysis (hazard ratio, 0.430; 95% confidence interval, 0.260-0.709; p = 0.001).We propose a cut-off value of 35% to best predict RFS in patients with surgically resected breast cancer. AR expression was positive in 68.4% of patients, and AR positivity was found to be an independent prognostic factor for longer RFS.CONCLUSIONWe propose a cut-off value of 35% to best predict RFS in patients with surgically resected breast cancer. AR expression was positive in 68.4% of patients, and AR positivity was found to be an independent prognostic factor for longer RFS. Endocrine therapy is a standard treatment for hormone receptor-positive breast cancer, which accounts for 60%-75% of all breast cancer. Hormone receptor positivity is a prognostic and predictive biomarker in breast cancer. Approximately 50%-80% of breast cancer is also positive for androgen receptor (AR), but the prognostic and predictive value of AR expression in breast cancer is controversial. Here, we investigated AR expression and its prognostic value in patients with surgically resected breast cancer in Korea. We retrospectively reviewed the medical records of patients who had surgically resected breast cancer to collect AR expression data and other clinicopathological data. The optimal cut-off for AR positivity was determined using a receiver operating characteristic curve analysis. We reviewed 957 patients with surgically resected breast cancer from June 2012 to April 2013. The median follow-up was 62 months, and relapse events occurred in 101 (10.6%) patients. Unlike the cut-off value of 1% or 10% in previous reports, 35% was determined to be best for predicting relapse-free survival (RFS) in this study. At the cut-off value of 35%, 654 (68.4%) patients were AR-positive. AR expression was more prevalent in luminal A (87.6%) and luminal B (73.1%) types than in human epidermal growth factor receptor 2-positive (56.2%) or triple-negative (20.6%) types. AR expression of ≥ 35% was significantly related to longer RFS in a multivariate analysis (hazard ratio, 0.430; 95% confidence interval, 0.260-0.709; = 0.001). We propose a cut-off value of 35% to best predict RFS in patients with surgically resected breast cancer. AR expression was positive in 68.4% of patients, and AR positivity was found to be an independent prognostic factor for longer RFS. Purpose: Endocrine therapy is a standard treatment for hormone receptor-positive breast cancer, which accounts for 60%–75% of all breast cancer. Hormone receptor positivity is a prognostic and predictive biomarker in breast cancer. Approximately 50%–80% of breast cancer is also positive for androgen receptor (AR), but the prognostic and predictive value of AR expression in breast cancer is controversial. Here, we investigated AR expression and its prognostic value in patients with surgically resected breast cancer in Korea. Methods: We retrospectively reviewed the medical records of patients who had surgically resected breast cancer to collect AR expression data and other clinicopathological data. The optimal cut-off for AR positivity was determined using a receiver operating characteristic curve analysis. Results: We reviewed 957 patients with surgically resected breast cancer from June 2012 to April 2013. The median follow-up was 62 months, and relapse events occurred in 101 (10.6%) patients. Unlike the cut-off value of 1% or 10% in previous reports, 35% was determined to be best for predicting relapse-free survival (RFS) in this study. At the cut-off value of 35%, 654 (68.4%) patients were AR-positive. AR expression was more prevalent in luminal A (87.6%) and luminal B (73.1%) types than in human epidermal growth factor receptor 2-positive (56.2%) or triple-negative (20.6%) types. AR expression of ≥ 35% was significantly related to longer RFS in a multivariate analysis (hazard ratio, 0.430; 95% confidence interval, 0.260– 0.709; p = 0.001). Conclusion: We propose a cut-off value of 35% to best predict RFS in patients with surgically resected breast cancer. AR expression was positive in 68.4% of patients, and AR positivity was found to be an independent prognostic factor for longer RFS. KCI Citation Count: 4 |
| Author | Min, Ahrum Ryu, Han Suk Han, Wonshik Park, In Ae Lee, Han-Byoel Yang, Yaewon Kim, Tae-Yong Lee, Kyung-Hun Suh, Koung Jin Noh, Dong-Young Moon, Hyeong-Gon Lee, Dae-Won Im, Seock-Ah Woo, Go-un |
| AuthorAffiliation | 3 Department of Internal Medicine, Chungbuk National University Hospital, Cheongju, Korea 8 Department of Surgery, Seoul National University Hospital, Seoul National University College of Medicine, Seoul, Korea 6 Department of Pathology, Seoul National University Hospital, Seoul National University College of Medicine, Seoul, Korea 4 Biomedical Research Institute, Seoul National University Hospital, Seoul, Korea 1 Cancer Research Institute, Seoul National University, Seoul, Korea 7 Department of Internal Medicine, Seoul National University Bundang Hospital, Seongnam, Korea 5 Department of Internal Medicine, Seoul National University Hospital, Seoul National University College of Medicine, Seoul, Korea 2 Translational Medicine, Seoul National University College of Medicine, Seoul, Korea |
| AuthorAffiliation_xml | – name: 5 Department of Internal Medicine, Seoul National University Hospital, Seoul National University College of Medicine, Seoul, Korea – name: 2 Translational Medicine, Seoul National University College of Medicine, Seoul, Korea – name: 4 Biomedical Research Institute, Seoul National University Hospital, Seoul, Korea – name: 8 Department of Surgery, Seoul National University Hospital, Seoul National University College of Medicine, Seoul, Korea – name: 3 Department of Internal Medicine, Chungbuk National University Hospital, Cheongju, Korea – name: 6 Department of Pathology, Seoul National University Hospital, Seoul National University College of Medicine, Seoul, Korea – name: 1 Cancer Research Institute, Seoul National University, Seoul, Korea – name: 7 Department of Internal Medicine, Seoul National University Bundang Hospital, Seongnam, Korea |
| Author_xml | – sequence: 1 givenname: Yaewon orcidid: 0000-0002-1773-134X surname: Yang fullname: Yang, Yaewon organization: Cancer Research Institute, Seoul National University, Seoul, Korea., Translational Medicine, Seoul National University College of Medicine, Seoul, Korea., Department of Internal Medicine, Chungbuk National University Hospital, Cheongju, Korea – sequence: 2 givenname: Ahrum orcidid: 0000-0003-3236-838X surname: Min fullname: Min, Ahrum organization: Cancer Research Institute, Seoul National University, Seoul, Korea., Biomedical Research Institute, Seoul National University Hospital, Seoul, Korea – sequence: 3 givenname: Kyung-Hun orcidid: 0000-0002-2390-3240 surname: Lee fullname: Lee, Kyung-Hun organization: Cancer Research Institute, Seoul National University, Seoul, Korea., Department of Internal Medicine, Seoul National University Hospital, Seoul National University College of Medicine, Seoul, Korea – sequence: 4 givenname: Han Suk orcidid: 0000-0003-2508-9796 surname: Ryu fullname: Ryu, Han Suk organization: Cancer Research Institute, Seoul National University, Seoul, Korea., Department of Pathology, Seoul National University Hospital, Seoul National University College of Medicine, Seoul, Korea – sequence: 5 givenname: Tae-Yong orcidid: 0000-0002-3930-6766 surname: Kim fullname: Kim, Tae-Yong organization: Cancer Research Institute, Seoul National University, Seoul, Korea., Department of Internal Medicine, Seoul National University Hospital, Seoul National University College of Medicine, Seoul, Korea – sequence: 6 givenname: Go-un orcidid: 0000-0002-2927-8271 surname: Woo fullname: Woo, Go-un organization: Translational Medicine, Seoul National University College of Medicine, Seoul, Korea., Department of Internal Medicine, Seoul National University Hospital, Seoul National University College of Medicine, Seoul, Korea – sequence: 7 givenname: Koung Jin orcidid: 0000-0002-1881-8738 surname: Suh fullname: Suh, Koung Jin organization: Translational Medicine, Seoul National University College of Medicine, Seoul, Korea., Department of Internal Medicine, Seoul National University Bundang Hospital, Seongnam, Korea – sequence: 8 givenname: Dae-Won orcidid: 0000-0001-7133-6669 surname: Lee fullname: Lee, Dae-Won organization: Cancer Research Institute, Seoul National University, Seoul, Korea., Translational Medicine, Seoul National University College of Medicine, Seoul, Korea., Department of Internal Medicine, Seoul National University Hospital, Seoul National University College of Medicine, Seoul, Korea – sequence: 9 givenname: Han-Byoel orcidid: 0000-0003-0152-575X surname: Lee fullname: Lee, Han-Byoel organization: Cancer Research Institute, Seoul National University, Seoul, Korea., Department of Surgery, Seoul National University Hospital, Seoul National University College of Medicine, Seoul, Korea – sequence: 10 givenname: Hyeong-Gon orcidid: 0000-0002-9981-0286 surname: Moon fullname: Moon, Hyeong-Gon organization: Cancer Research Institute, Seoul National University, Seoul, Korea., Department of Surgery, Seoul National University Hospital, Seoul National University College of Medicine, Seoul, Korea – sequence: 11 givenname: Wonshik orcidid: 0000-0001-7310-0764 surname: Han fullname: Han, Wonshik organization: Cancer Research Institute, Seoul National University, Seoul, Korea., Department of Surgery, Seoul National University Hospital, Seoul National University College of Medicine, Seoul, Korea – sequence: 12 givenname: In Ae orcidid: 0000-0002-8759-4934 surname: Park fullname: Park, In Ae organization: Cancer Research Institute, Seoul National University, Seoul, Korea., Department of Pathology, Seoul National University Hospital, Seoul National University College of Medicine, Seoul, Korea – sequence: 13 givenname: Dong-Young orcidid: 0000-0001-9418-7256 surname: Noh fullname: Noh, Dong-Young organization: Cancer Research Institute, Seoul National University, Seoul, Korea., Department of Internal Medicine, Seoul National University Bundang Hospital, Seongnam, Korea – sequence: 14 givenname: Seock-Ah orcidid: 0000-0002-5396-6533 surname: Im fullname: Im, Seock-Ah organization: Cancer Research Institute, Seoul National University, Seoul, Korea., Biomedical Research Institute, Seoul National University Hospital, Seoul, Korea., Department of Internal Medicine, Seoul National University Hospital, Seoul National University College of Medicine, Seoul, Korea |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/32395377$$D View this record in MEDLINE/PubMed https://www.kci.go.kr/kciportal/ci/sereArticleSearch/ciSereArtiView.kci?sereArticleSearchBean.artiId=ART002582059$$DAccess content in National Research Foundation of Korea (NRF) |
| BookMark | eNqFUU1v1DAUtFAR3RbO3JCPcMjWX4njC9KyWqBSJaqlnC3HeVncZu1gJ8D-exy2fB7g9J79Zt54xmfoxAcPCD2lZCmIqC9uG7tkhJEl40tg9QO0YESxQilCTtCCSl4XlSyrU3SW0i0hleBSPkKnnHFV5naB7HUMOx_S6Czehh5w6PDKt_kSPN6ChWEMEW--DhFScsFj5_H7Ke6cNX1_yIgEdoQWb0zMx1cRTBrx2ngLEV-b0YEf02P0sDN9gif39Rx9eL25Wb8trt69uVyvrgormByLhnDZ1I2qCICSslVGCsmaFmzZ0oqXnRUttFKVALVoKkNoW7KmskIoUTWE8XP04rjXx07fWaeDcd_rLui7qFfbm0tdCyklLTOWHLGTH8zhSzajh-j2Jh40JXrOVuds9ZytZlznbDPl5ZEyTM0eWputRfOLNov9OfHuY5b-rCVVTIr5fc_vF8TwaYI06r1LFvreeAhT0kwQWlOuJM3QZ79r_RT58XEZUB4BNoaUInTaujHnHWZp1__DxMVfvP_Z_gbMer5G |
| CitedBy_id | crossref_primary_10_3390_cancers13092218 crossref_primary_10_3390_jpm12121988 crossref_primary_10_3389_fcell_2020_579160 crossref_primary_10_4143_crt_2022_834 crossref_primary_10_1007_s10549_023_07014_x crossref_primary_10_1016_j_mce_2021_111324 crossref_primary_10_5858_arpa_2021_0590_OA crossref_primary_10_2174_1871520621666211201150818 crossref_primary_10_3390_jpm12020261 crossref_primary_10_34014_2227_1848_2022_3_49_60 |
| Cites_doi | 10.3322/caac.21492 10.1371/journal.pone.0128368 10.1016/j.breast.2014.02.013 10.5858/arpa.2018-0902-SA 10.3816/CBC.2010.n.038 10.1007/s12282-012-0337-2 10.4143/crt.2019.138 10.1186/1471-2164-7-96 10.1186/1471-2407-7-203 10.1210/me.2012-1107 10.4137/CMO.S18006 10.3390/cancers6031351 10.1158/1078-0432.CCR-17-1199 10.1093/jnci/djp082 10.1093/annonc/mdt303 10.1073/pnas.191367098 10.1200/JCO.2010.30.3677 10.1093/annonc/mdr304 10.1038/35021093 10.1097/PAS.0000000000000728 10.1186/1471-2407-14-958 10.1200/JCO.2012.43.4134 10.1007/s00428-006-0213-6 10.1038/modpathol.2009.159 10.1016/j.tranon.2018.05.006 10.1200/JCO.1988.6.7.1076 10.1172/JCI45014 10.1200/JCO.2008.18.1370 |
| ContentType | Journal Article |
| Copyright | 2020 Korean Breast Cancer Society. 2020 Korean Breast Cancer Society 2020 Korean Breast Cancer Society |
| Copyright_xml | – notice: 2020 Korean Breast Cancer Society. – notice: 2020 Korean Breast Cancer Society 2020 Korean Breast Cancer Society |
| DBID | AAYXX CITATION NPM 7X8 5PM ADTOC UNPAY ACYCR |
| DOI | 10.4048/jbc.2020.23.e28 |
| DatabaseName | CrossRef PubMed MEDLINE - Academic PubMed Central (Full Participant titles) Unpaywall for CDI: Periodical Content Unpaywall Korean Citation Index |
| DatabaseTitle | CrossRef PubMed MEDLINE - Academic |
| DatabaseTitleList | MEDLINE - Academic PubMed |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: UNPAY name: Unpaywall url: https://proxy.k.utb.cz/login?url=https://unpaywall.org/ sourceTypes: Open Access Repository |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine |
| EISSN | 2092-9900 |
| EndPage | 193 |
| ExternalDocumentID | oai_kci_go_kr_ARTI_8477715 10.4048/jbc.2020.23.e28 PMC7192742 32395377 10_4048_jbc_2020_23_e28 |
| Genre | Journal Article |
| GroupedDBID | --- 5-W 5GY 8JR 8XY 9ZL AAYXX ADBBV ADRAZ AENEX ALMA_UNASSIGNED_HOLDINGS AOIJS BAWUL CITATION DIK DU5 EF. GROUPED_DOAJ HYE KQ8 M48 O5R O5S PGMZT RPM NPM 7X8 5PM ADTOC UNPAY ACYCR |
| ID | FETCH-LOGICAL-c427t-b037b8b960ee977d9a7472bdec5d1635fc4ded795ee84b6a01d52b6c44946b023 |
| IEDL.DBID | M48 |
| ISSN | 1738-6756 2092-9900 |
| IngestDate | Sun Mar 09 07:51:27 EDT 2025 Sun Sep 07 11:22:59 EDT 2025 Thu Aug 21 18:03:25 EDT 2025 Fri Jul 11 09:21:45 EDT 2025 Thu Jan 02 22:52:14 EST 2025 Tue Jul 01 01:56:44 EDT 2025 Thu Apr 24 23:06:50 EDT 2025 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 2 |
| Keywords | Breast Recurrence Carcinoma Survival Receptors, androgen |
| Language | English |
| License | 2020 Korean Breast Cancer Society. This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (https://creativecommons.org/licenses/by-nc/4.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited. cc-by-nc |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c427t-b037b8b960ee977d9a7472bdec5d1635fc4ded795ee84b6a01d52b6c44946b023 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 https://ejbc.kr/search.php?where=aview&id=10.4048/jbc.2020.23.e28&code=0096JBC&vmode=FULL |
| ORCID | 0000-0001-9418-7256 0000-0002-2927-8271 0000-0003-2508-9796 0000-0002-3930-6766 0000-0001-7133-6669 0000-0003-3236-838X 0000-0002-1773-134X 0000-0002-9981-0286 0000-0002-1881-8738 0000-0003-0152-575X 0000-0002-8759-4934 0000-0002-5396-6533 0000-0001-7310-0764 0000-0002-2390-3240 |
| OpenAccessLink | http://journals.scholarsportal.info/openUrl.xqy?doi=10.4048/jbc.2020.23.e28 |
| PMID | 32395377 |
| PQID | 2401813971 |
| PQPubID | 23479 |
| PageCount | 12 |
| ParticipantIDs | nrf_kci_oai_kci_go_kr_ARTI_8477715 unpaywall_primary_10_4048_jbc_2020_23_e28 pubmedcentral_primary_oai_pubmedcentral_nih_gov_7192742 proquest_miscellaneous_2401813971 pubmed_primary_32395377 crossref_citationtrail_10_4048_jbc_2020_23_e28 crossref_primary_10_4048_jbc_2020_23_e28 |
| ProviderPackageCode | CITATION AAYXX |
| PublicationCentury | 2000 |
| PublicationDate | 2020-04-01 |
| PublicationDateYYYYMMDD | 2020-04-01 |
| PublicationDate_xml | – month: 04 year: 2020 text: 2020-04-01 day: 01 |
| PublicationDecade | 2020 |
| PublicationPlace | Korea (South) |
| PublicationPlace_xml | – name: Korea (South) |
| PublicationTitle | Journal of breast cancer |
| PublicationTitleAlternate | J Breast Cancer |
| PublicationYear | 2020 |
| Publisher | Korean Breast Cancer Society 한국유방암학회 |
| Publisher_xml | – name: Korean Breast Cancer Society – name: 한국유방암학회 |
| References | Vallejos (10.4048/jbc.2020.23.e28_ref24) 2010; 10 Goldhirsch (10.4048/jbc.2020.23.e28_ref16) 2013; 24 Parker (10.4048/jbc.2020.23.e28_ref19) 2009; 27 Cheang (10.4048/jbc.2020.23.e28_ref15) 2009; 101 Na (10.4048/jbc.2020.23.e28_ref13) 2016; 40 Perou (10.4048/jbc.2020.23.e28_ref20) 2000; 406 Hu (10.4048/jbc.2020.23.e28_ref18) 2006; 7 Lakis (10.4048/jbc.2020.23.e28_ref7) 2014; 23 Jung (10.4048/jbc.2020.23.e28_ref2) 2019; 51 Schippinger (10.4048/jbc.2020.23.e28_ref29) 2006; 449 Goldhirsch (10.4048/jbc.2020.23.e28_ref23) 2011; 22 Bray (10.4048/jbc.2020.23.e28_ref1) 2018; 68 Dai (10.4048/jbc.2020.23.e28_ref22) 2015; 5 Hickey (10.4048/jbc.2020.23.e28_ref11) 2012; 26 Lehmann (10.4048/jbc.2020.23.e28_ref6) 2011; 121 Keam (10.4048/jbc.2020.23.e28_ref12) 2007; 7 Bartlett (10.4048/jbc.2020.23.e28_ref4) 2011; 29 Honma (10.4048/jbc.2020.23.e28_ref25) 2012; 20 Inic (10.4048/jbc.2020.23.e28_ref5) 2014; 8 Pistelli (10.4048/jbc.2020.23.e28_ref27) 2014; 6 Fisher (10.4048/jbc.2020.23.e28_ref3) 1988; 6 Bronte (10.4048/jbc.2020.23.e28_ref9) 2018; 11 Ricciardi (10.4048/jbc.2020.23.e28_ref28) 2015; 10 Wolff (10.4048/jbc.2020.23.e28_ref14) 2018; 142 Prat (10.4048/jbc.2020.23.e28_ref17) 2013; 31 Doberstein (10.4048/jbc.2020.23.e28_ref26) 2014; 14 Niemeier (10.4048/jbc.2020.23.e28_ref8) 2010; 23 Sørlie (10.4048/jbc.2020.23.e28_ref21) 2001; 98 Ricciardelli (10.4048/jbc.2020.23.e28_ref10) 2018; 24 |
| References_xml | – volume: 68 start-page: 394 year: 2018 ident: 10.4048/jbc.2020.23.e28_ref1 publication-title: CA Cancer J Clin doi: 10.3322/caac.21492 – volume: 10 start-page: e0128368 year: 2015 ident: 10.4048/jbc.2020.23.e28_ref28 publication-title: PLoS One doi: 10.1371/journal.pone.0128368 – volume: 23 start-page: 234 year: 2014 ident: 10.4048/jbc.2020.23.e28_ref7 publication-title: Breast doi: 10.1016/j.breast.2014.02.013 – volume: 142 start-page: 1364 year: 2018 ident: 10.4048/jbc.2020.23.e28_ref14 publication-title: Arch Pathol Lab Med doi: 10.5858/arpa.2018-0902-SA – volume: 10 start-page: 294 year: 2010 ident: 10.4048/jbc.2020.23.e28_ref24 publication-title: Clin Breast Cancer doi: 10.3816/CBC.2010.n.038 – volume: 20 start-page: 323 year: 2012 ident: 10.4048/jbc.2020.23.e28_ref25 publication-title: Breast Cancer doi: 10.1007/s12282-012-0337-2 – volume: 51 start-page: 417 year: 2019 ident: 10.4048/jbc.2020.23.e28_ref2 publication-title: Cancer Res Treat doi: 10.4143/crt.2019.138 – volume: 7 start-page: 96 year: 2006 ident: 10.4048/jbc.2020.23.e28_ref18 publication-title: BMC Genomics doi: 10.1186/1471-2164-7-96 – volume: 7 start-page: 203 year: 2007 ident: 10.4048/jbc.2020.23.e28_ref12 publication-title: BMC Cancer doi: 10.1186/1471-2407-7-203 – volume: 26 start-page: 1252 year: 2012 ident: 10.4048/jbc.2020.23.e28_ref11 publication-title: Mol Endocrinol doi: 10.1210/me.2012-1107 – volume: 8 start-page: 107 year: 2014 ident: 10.4048/jbc.2020.23.e28_ref5 publication-title: Clin Med Insights Oncol doi: 10.4137/CMO.S18006 – volume: 6 start-page: 1351 year: 2014 ident: 10.4048/jbc.2020.23.e28_ref27 publication-title: Cancers (Basel) doi: 10.3390/cancers6031351 – volume: 24 start-page: 2328 year: 2018 ident: 10.4048/jbc.2020.23.e28_ref10 publication-title: Clin Cancer Res doi: 10.1158/1078-0432.CCR-17-1199 – volume: 101 start-page: 736 year: 2009 ident: 10.4048/jbc.2020.23.e28_ref15 publication-title: J Natl Cancer Inst doi: 10.1093/jnci/djp082 – volume: 24 start-page: 2206 year: 2013 ident: 10.4048/jbc.2020.23.e28_ref16 publication-title: Ann Oncol doi: 10.1093/annonc/mdt303 – volume: 98 start-page: 10869 year: 2001 ident: 10.4048/jbc.2020.23.e28_ref21 publication-title: Proc Natl Acad Sci U S A doi: 10.1073/pnas.191367098 – volume: 29 start-page: 1531 year: 2011 ident: 10.4048/jbc.2020.23.e28_ref4 publication-title: J Clin Oncol doi: 10.1200/JCO.2010.30.3677 – volume: 22 start-page: 1736 year: 2011 ident: 10.4048/jbc.2020.23.e28_ref23 publication-title: Ann Oncol doi: 10.1093/annonc/mdr304 – volume: 406 start-page: 747 year: 2000 ident: 10.4048/jbc.2020.23.e28_ref20 publication-title: Nature doi: 10.1038/35021093 – volume: 40 start-page: 1622 year: 2016 ident: 10.4048/jbc.2020.23.e28_ref13 publication-title: Am J Surg Pathol doi: 10.1097/PAS.0000000000000728 – volume: 14 start-page: 958 year: 2014 ident: 10.4048/jbc.2020.23.e28_ref26 publication-title: BMC Cancer doi: 10.1186/1471-2407-14-958 – volume: 5 start-page: 2929 year: 2015 ident: 10.4048/jbc.2020.23.e28_ref22 publication-title: Am J Cancer Res – volume: 31 start-page: 203 year: 2013 ident: 10.4048/jbc.2020.23.e28_ref17 publication-title: J Clin Oncol doi: 10.1200/JCO.2012.43.4134 – volume: 449 start-page: 24 year: 2006 ident: 10.4048/jbc.2020.23.e28_ref29 publication-title: Virchows Arch doi: 10.1007/s00428-006-0213-6 – volume: 23 start-page: 205 year: 2010 ident: 10.4048/jbc.2020.23.e28_ref8 publication-title: Mod Pathol doi: 10.1038/modpathol.2009.159 – volume: 11 start-page: 950 year: 2018 ident: 10.4048/jbc.2020.23.e28_ref9 publication-title: Transl Oncol doi: 10.1016/j.tranon.2018.05.006 – volume: 6 start-page: 1076 year: 1988 ident: 10.4048/jbc.2020.23.e28_ref3 publication-title: J Clin Oncol doi: 10.1200/JCO.1988.6.7.1076 – volume: 121 start-page: 2750 year: 2011 ident: 10.4048/jbc.2020.23.e28_ref6 publication-title: J Clin Invest doi: 10.1172/JCI45014 – volume: 27 start-page: 1160 year: 2009 ident: 10.4048/jbc.2020.23.e28_ref19 publication-title: J Clin Oncol doi: 10.1200/JCO.2008.18.1370 |
| SSID | ssj0064377 |
| Score | 2.2278633 |
| Snippet | Endocrine therapy is a standard treatment for hormone receptor-positive breast cancer, which accounts for 60%-75% of all breast cancer. Hormone receptor... Purpose: Endocrine therapy is a standard treatment for hormone receptor-positive breast cancer, which accounts for 60%–75% of all breast cancer. Hormone... |
| SourceID | nrf unpaywall pubmedcentral proquest pubmed crossref |
| SourceType | Open Website Open Access Repository Aggregation Database Index Database Enrichment Source |
| StartPage | 182 |
| SubjectTerms | Original 일반외과학 |
| SummonAdditionalLinks | – databaseName: Unpaywall dbid: UNPAY link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlV1Lb9QwEB7RrQS98IaGlwziAIesso4TJ8dStVqQqFbASuVkxY5Tlo2cVZoIyq9nJsmuulAEnKLITvwae76RP38GeIlDnCFyyH30zdIXRgo_QT-GoUocTrLUoA_uCLIn8XQu3p1Gp4NIEp2FubR_L0hS9qsmnUFOhOWx5ckO7Ma0kzSC3fnJ7OBzd9wRpyzC3u4auSDlPq6vQS_ic9UftvzPjquLq6Dl7wzJG61bZRffsrK85H6Ob8F0XfGedbIct40emx-_aDr-Q8tuw80BgrKD3mbuwDXr7sL198Mm-z0ws7oi-h0msw9VaVlVMOI9VmhrDGGmXWGczo6-DxRaxxaOfWzrbgktLxhx-QziWNZpJ7M3xHpv2CFZV81mvYzr-X2YHx99Opz6w10MvhFcNr4OQqkTjfGOtQgZ8zTDOITr3JooR0gXFUbkNpdpZG0idIzjn0dcx0aIVMQagcEDGLnK2X1gsUWLKIQQBcZ-kQkydJA8C2xskqKQ1nowXo-QMoNQOd2XUSoMWKjrFHadoq5TPFTYdR682nyw6jU6_pz1BQ65WpqFIl1tep5ValkrjB7eKqyIlJPIg-dri1A42WgHJXO2as8Vwh9ERAjhJh487C1kU2LIwzQKpfRAbtnOJgMVuJ3iFl86QW-JMFsK7sHrjZX9rSGP_iPvY9ijt55v9ARGTd3apwilGv1smEY_ARnjF1M priority: 102 providerName: Unpaywall |
| Title | Prognostic Role of Androgen Receptor Expression in Surgically Resected Early Breast Cancer Patients |
| URI | https://www.ncbi.nlm.nih.gov/pubmed/32395377 https://www.proquest.com/docview/2401813971 https://pubmed.ncbi.nlm.nih.gov/PMC7192742 https://doi.org/10.4048/jbc.2020.23.e28 https://www.kci.go.kr/kciportal/ci/sereArticleSearch/ciSereArtiView.kci?sereArticleSearchBean.artiId=ART002582059 |
| UnpaywallVersion | publishedVersion |
| Volume | 23 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| ispartofPNX | Journal of Breast Cancer, 2020, 23(2), 94, pp.182-193 |
| journalDatabaseRights | – providerCode: PRVAFT databaseName: Open Access Digital Library customDbUrl: eissn: 2092-9900 dateEnd: 99991231 omitProxy: true ssIdentifier: ssj0064377 issn: 2092-9900 databaseCode: KQ8 dateStart: 20110101 isFulltext: true titleUrlDefault: http://grweb.coalliance.org/oadl/oadl.html providerName: Colorado Alliance of Research Libraries – providerCode: PRVAON databaseName: DOAJ Directory of Open Access Journals customDbUrl: eissn: 2092-9900 dateEnd: 99991231 omitProxy: true ssIdentifier: ssj0064377 issn: 2092-9900 databaseCode: DOA dateStart: 19980101 isFulltext: true titleUrlDefault: https://www.doaj.org/ providerName: Directory of Open Access Journals – providerCode: PRVBFR databaseName: Free Medical Journals customDbUrl: eissn: 2092-9900 dateEnd: 99991231 omitProxy: true ssIdentifier: ssj0064377 issn: 2092-9900 databaseCode: DIK dateStart: 20110101 isFulltext: true titleUrlDefault: http://www.freemedicaljournals.com providerName: Flying Publisher – providerCode: PRVERR databaseName: KoreaMed Open Access customDbUrl: eissn: 2092-9900 dateEnd: 99991231 omitProxy: true ssIdentifier: ssj0064377 issn: 2092-9900 databaseCode: 5-W dateStart: 20050101 isFulltext: true titleUrlDefault: https://koreamed.org/journals providerName: Korean Association of Medical Journal Editors – providerCode: PRVAQN databaseName: PubMed Central customDbUrl: eissn: 2092-9900 dateEnd: 99991231 omitProxy: true ssIdentifier: ssj0064377 issn: 2092-9900 databaseCode: RPM dateStart: 20110101 isFulltext: true titleUrlDefault: https://www.ncbi.nlm.nih.gov/pmc/ providerName: National Library of Medicine – providerCode: PRVFZP databaseName: Scholars Portal Journals: Open Access customDbUrl: eissn: 2092-9900 dateEnd: 20250630 omitProxy: true ssIdentifier: ssj0064377 issn: 2092-9900 databaseCode: M48 dateStart: 20110301 isFulltext: true titleUrlDefault: http://journals.scholarsportal.info providerName: Scholars Portal |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwjV1Nb9NAFHyirQS9IL5rPqIFcYCDo2S99tonVKpWBalVBEQqp5V3vYZQyw5OIpp_z6ztGiKC4GRZ_va89ZvnHc0jegmIUzCHzEdulr4wUvgx8hhKlSgYp4lBDm4EsufR6VS8vwgvfrUD6l7gYmtp5_pJTetiePV9_QYDHvx1KJzt7DftvAi5EzUPLY93aA9pibsQPxP9lIKboGo6rUiMcLDkqPX52XaCjRS1U9b5Nvb5p4jy1qqcp-sfaVH8lqFO7tDtjlqywzYW7tINW96jm2fd5Pl9MpO6crI6bGYfqsKyKmdOz1ghhhjoo52j_mbHV500tmSzkn1c1c2nsVgzp9Ez4Kes8URmb52afcmOXNTUbNLasy4e0PTk-NPRqd_1WPCN4HLp61EgdaxRx1gLKpglKeoLrjNrwgxULcyNyGwmk9DaWOgIuGYh15ERIhGRRsJ_SLtlVdoDYpEF0rkQIkdNF5pRisTH05GNTJzn0lqPhtevVZnOgNz1wSgUChGHgwIOyuGgeKCAg0ev-gPmrffG33d9AZzUpZkp55ftll8qdVkrVAXvFG5EynHo0fNrGBUGkZsZSUtbrRYKtAZMB9Rs7NGjFtb-igEPkhCx45HcALzfwV1wc0s5-9oYdUvQZym4R6_70PjXgzz-_2d-QvturZURPaXdZb2yz8CQlnrQ_FkYNPE_aH5gDWhvej45_PwTBSsQ5w |
| linkProvider | Scholars Portal |
| linkToUnpaywall | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlV1Lb9QwEB7RrQS98IaGlwziAIesso4TJ8dStVqQqFbASuVkxY5Tlo2cVZoIyq9nJsmuulAEnKLITvwae76RP38GeIlDnCFyyH30zdIXRgo_QT-GoUocTrLUoA_uCLIn8XQu3p1Gp4NIEp2FubR_L0hS9qsmnUFOhOWx5ckO7Ma0kzSC3fnJ7OBzd9wRpyzC3u4auSDlPq6vQS_ic9UftvzPjquLq6Dl7wzJG61bZRffsrK85H6Ob8F0XfGedbIct40emx-_aDr-Q8tuw80BgrKD3mbuwDXr7sL198Mm-z0ws7oi-h0msw9VaVlVMOI9VmhrDGGmXWGczo6-DxRaxxaOfWzrbgktLxhx-QziWNZpJ7M3xHpv2CFZV81mvYzr-X2YHx99Opz6w10MvhFcNr4OQqkTjfGOtQgZ8zTDOITr3JooR0gXFUbkNpdpZG0idIzjn0dcx0aIVMQagcEDGLnK2X1gsUWLKIQQBcZ-kQkydJA8C2xskqKQ1nowXo-QMoNQOd2XUSoMWKjrFHadoq5TPFTYdR682nyw6jU6_pz1BQ65WpqFIl1tep5ValkrjB7eKqyIlJPIg-dri1A42WgHJXO2as8Vwh9ERAjhJh487C1kU2LIwzQKpfRAbtnOJgMVuJ3iFl86QW-JMFsK7sHrjZX9rSGP_iPvY9ijt55v9ARGTd3apwilGv1smEY_ARnjF1M |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Prognostic+Role+of+Androgen+Receptor+Expression+in+Surgically+Resected+Early+Breast+Cancer+Patients&rft.jtitle=Journal+of+breast+cancer&rft.au=Yang%2C+Yaewon&rft.au=Min%2C+Ahrum&rft.au=Lee%2C+Kyung-Hun&rft.au=Ryu%2C+Han+Suk&rft.date=2020-04-01&rft.issn=1738-6756&rft.eissn=2092-9900&rft.volume=23&rft.issue=2&rft.spage=182&rft_id=info:doi/10.4048%2Fjbc.2020.23.e28&rft.externalDBID=n%2Fa&rft.externalDocID=10_4048_jbc_2020_23_e28 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1738-6756&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1738-6756&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1738-6756&client=summon |